Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02528357 |
| Title | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | GlaxoSmithKline |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | NLD | FRA | CAN |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Boston | Massachusetts | 02215 | United States | Details | |
| GSK Investigational Site | New York | New York | 10016 | United States | Details | |
| GSK Investigational Site | New York | New York | 10065 | United States | Details | |
| GSK Investigational Site | Nashville | Tennessee | 37203 | United States | Details | |
| GSK Investigational Site | Houston | Texas | 77030 | United States | Details | |
| GSK Investigational Site | Toronto | Ontario | M5G 2M9 | Canada | Details | |
| GSK Investigational Site | Villejuif | 94805 | France | Details | ||
| GSK Investigational Site | Amsterdam | 1066 CX | Netherlands | Details |